Photo: JGI/Tom Grill/Blend Images/Getty Images

照片：JGI/TomGrill/Blend Images/Getty Images

DarioHealth, a digital chronic condition management platform, reported $3.6 million in revenue for Q4 2023 compared to $6.8 million for the fourth quarter of 2022, a 47% decrease, and year-over-year revenue in 2023 was $20.4 million compared to $27.7 million for 2022.

数字慢性病管理平台DarioHealth报告2023年第四季度收入360万美元，而2022年第四季度收入为680万美元，下降了47%，2023年收入为2040万美元，而2022年收入为2770万美元。

The New York-based company said the overall decrease in revenue stemmed from lower consumer and strategic partner channels.

这家总部位于纽约的公司表示，收入的总体下降源于较低的消费者和战略合作伙伴渠道。

The company reported a net loss for the fourth quarter of $14.3 million compared to a loss of $12.6 million in Q4 2022, an increase of 13.2%. It reported year-over-year net loss of $59.4 million for 2023 compared to $62.2 million in 2022.

该公司第四季度净亏损1430万美元，而2022年第四季度亏损1260万美元，增幅为13.2%。该公司报告称，2023年同比净亏损5940万美元，而2022年为6220万美元。

DarioHealth's gross profit decreased substantially from $2.7 million in Q4 2022 to $132,000 in Q4 2023. Its yearly gross profit decreased 38% for 2023 to $6 million, compared to $9.7 million in 2022.

DarioHealth的毛利润从2022年第四季度的270万美元大幅下降至2023年第四季度的132000美元。2023年，其年度毛利润下降了38%，降至600万美元，而2022年为970万美元。

Total operating expenses for Q4 2023 were $14.3 million compared with $11.7 million for Q4 2022, and full-year expenditures were $62.2 million compared to $66.5 million for 2022, a 6.5% decrease.

2023年第四季度的总运营费用为1430万美元，而2022年第四季度为1170万美元，全年支出为6220万美元，而2022年为6650万美元，下降了6.5%。

Pro forma gross profit for 2023 was $10.4 million, which did not include $4.4 million of costs related to acquisitions and amortization expenses. This is compared to a pro forma gross profit of $14 million in 2022. The decrease was attributed to lower revenues from the strategic channel.

2023年的预计毛利润为1040万美元，其中不包括440万美元的收购和摊销费用。相比之下，2022年的预计毛利润为1400万美元。减少的原因是战略渠道收入减少。

'2023 was a very significant year for Dario. Our financial profile continued to improve as a result of our pivot to a Business-to-Business-to-Consumer business model with growing B2B2C revenue and decreasing operating costs,' Dario's CEO Erez Raphael said in a statement.

达里奥的首席执行官埃雷斯·拉斐尔（ErezRaphael）在一份声明中说，2023年对达里奥来说是非常重要的一年。由于我们转向了企业对企业对消费者的商业模式，B2B2B2C收入不断增长，运营成本不断降低，我们的财务状况持续改善。

'Last month, we announced the transformational acquisition of Twill, Inc., accompanied by a $22.4 million equity financing. We believe this acquisition propels Dario forward, creating immediate scale with three of the top eight national health plans, some of the largest technology companies and several major pharmaceutical companies as customers.'.

“上个月，我们宣布对Twill，Inc.进行转型收购，同时提供2240万美元的股权融资。我们相信，此次收购推动了达里奥的发展，创造了立竿见影的规模，拥有八大国家卫生计划中的三个，一些最大的科技公司和几家主要制药公司作为客户。”。

THE LARGER TREND

更大的趋势

In February, DarioHealth announced it would acquire Twill, a digital therapeutics company, to expand its offerings focused on chronic conditions.

2月，DarioHealth宣布将收购数字治疗公司Twill，以扩大其针对慢性病的产品。

At the time of the announcement, the company said it expected the acquisition to accelerate its path to profitability and nearly double its pro forma revenues in 2023.

在宣布时，该公司表示，预计此次收购将加速其盈利道路，并在2023年将其预计收入增加近一倍。

The expectation of increased pro forma revenues was based on revenues through Sept. 30 totaling $30.5 million, comprising $13.8 million in Twill revenues and $16.7 million in Dario revenues.

预计预计收入增加是基于截至9月30日总收入3050万美元，其中包括1380万美元的Twill收入和1670万美元的Dario收入。

DarioHealth (DRIO) is trading on the NASDAQ at $1.53 per share as of this article, a substantial drop from its opening price of $4,986 per share in 2013. The company's stock has steadily remained under $100 per share since 2017, gradually decreasing.

截至本文发布之日，DarioHealth（DRIO）在纳斯达克的股价为每股1.53美元，较2013年每股4986美元的开盘价大幅下跌。自2017年以来，该公司的股票一直稳定在每股100美元以下，并逐渐下降。

In DarioHealth's Q4 and full-year earnings report, the company said it has enhanced its path to profitability through improvements in its financial profile, which it expects to continue and accelerate in 2024 thanks to its acquisition of Twill.

在DarioHealth的第四季度和全年收益报告中，该公司表示，通过改善财务状况，该公司已增强了盈利能力。由于收购Twill，该公司预计2024年财务状况将继续并加速改善。

Tags: DarioHealth, chronic condition management, earnings

标签：DarioHealth，慢性病管理，收益

More regional news

更多地区新闻

Brightside Health secures $33 million in Series C fundingBy Trevor DermodyMarch 28, 2024

Brightside Health获得3300万美元的C系列资金Trevor DermodyMarch 282024

Pelago scores $58M to scale virtual clinic for substance use managementBy Jessica HagenMarch 28, 2024

Pelago获得5800万美元用于物质使用管理的虚拟诊所规模

Abridge brings generative AI solution to Sutter Health physicians in CaliforniaBy Trevor DermodyMarch 28, 2024

Abridge为加利福尼亚州的萨特健康医生带来了生成性人工智能解决方案Trevor DermodyMarch 2024